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A B S T R A C T To better understand how heparin
structure affects its activity the relationships between
the functional domains for inhibitor binding and
charge density were investigated to determine how
these domains affect heparin-mediated thrombin in-
hibition by two different heparin-dependent protease
inhibitors, antithrombin (AT) and heparin cofactor II
(HC II). A series of heparins, fractionated systemati-
cally by charge density, was further fractionated on
antithrombin agarose to isolate more homogeneous
subfractions that were either inactive or highly active
with respect to thrombin inhibition by AT. With AT,
the activities of the AT-active subfractions increased
sharply with heparin charge density, while those with
little or no affinity for AT were virtually inactive. In
contrast, with HC II inhibitor, the activities of the
heparins depended only upon their charge densities
and were independent of AT affinity. At any given
charge density, the heparin before fractionation by AT
affinity and the fractions that were highly active and
inactive with AT were all equally active with HC II.
The two inhibitors also differed in their reactivity with
heparan sulfate and dermatan sulfate. A charge-den-
sity effect with the subfractions having similar high
affinity for AT demonstrates that charge density rep-
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resents a heparin functional domain that is indepen-
dent of the AT-binding domain. The behavior of the
AT-inactive heparins, being fully active with HC II,
demonstrates the functional domain necessary for AT
binding is not needed to produce HC II activity.
INTRODUCTION
The polysaccharide heparin catalyzes the reaction be-
tween antithrombin (AT)' and several serine proteases,
and between heparin cofactor II (HC II) (1) and
thrombin. How structure affects activity is not gen-
erally well known, and only in the case of AT binding
has a physical structure been identified as being re-
sponsible for a given function. A short sequence of
defined structure (2) is necessary for AT-heparin bind-
ing and, hence, activity with AT (3, 4). Because ad-
ditional properties such as molecular weight (5, 6),
thrombin affinity (6-8), and charge density (9-12), can
also markedly affect the activity of a heparin, the
molecule must have multiple functional domains
(6, 7).
In this paper we report investigations to determine
whether heparin functional domains required for ac-
' Abbreviations used in this paper: AT, antithrombin II/
III, also heparin cofactor I; C50", concentration of glycosa-
minoglycan producing 50% thrombin inhibition under stan-
dard conditions;CR50', relative concentrations of glycosa-
minoglycan and standard heparin producing 50% thrombin
inhibition under standard conditions; HA heparin, heparin
with high affinity for AT; HC II, heparin cofactor II; LA
heparin, heparin with low affinity for AT; VLA heparin,
heparin with very low affinity for AT: Z, heparin linear
charge density.
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tivity with AT also are important for thrombin inhi-
bition with HC II. Our approach was to systematically
fractionate heparin to functionally separate the effects
of heparin charge density and AT affinity. It was
thereby possible to investigate the roles of such func-
tional domains without physically isolating or identi-
fying the structures involved. By comparing the roles
of different functional domains with two different in-
hibitors, it was possible to determine which domains
are specific to a given inhibitor and which are general
features of the mechanism of heparin catalysis. By
learning how functionally different heparins act with
these two different inhibitors, it may be possible to
better understand the complex activity of heteroge-
neous heparin.
METHODS
Heparin fractionation. Hog mucosal heparin (176 U. S.
Pharmacopeia, units per milligram; Diosynth BV, Holland)
was fractionated by two-phase partition (10, 12) to obtain
heparin fractions, previously characterized in detail (9-12),
that vary systematically in linear charge density, Z. The
highly purified and more homogeneous fractions have sim-
ilar molecular-weight distributions, with an average molec-
ular weight of 15,000, and contain no detectable dermatan
sulfate or other contaminating glycosaminoglycans. Five of
the nine fractions were further fractionated by AT-agarose
affinity chromatography (4) (see Table I). The size distri-
butions of the high affinity (HA) and very low affinity (VLA)
subfractions of fraction 3 (Z = 2.71) were compared by pass-
ing each through a column (0.8 cm X 60 cm) of 6% agarose
(4-0.5 m; Bio-Rad Laboratories, Richmond, CA) and 0.5-ml
fractions were collected and analyzed for uronate as de-
scribed previously (9).
Inhibitor, protease, and polysaccharide preparation.
Human a-thrombin was prepared as described previously
(13). Human AT isolated by heparin-agarose affinity chro-
TABLE I
Physical Characteristics and Distribution by AT Affinity of
Charge-Density Fractionated Heparins
Percent eluting with
Charge 0.05 M NaCI 0.30 M NaCI 3.0 M NaCI
Fraction densityt (VLA) (LA) (HA)
1 2.48 70 9 21
2 2.64 60 1 1 29
3 2.71 52§ 15 33§
4 2.73 47 14 39
5 2.85 43 21 36
1 mg heparin was fractionated on 6.5-ml AT-agarose column by
stepwise elution with two bed volumes of the indicated concentra-
tion of NaCl in 0.05 M Tris, pH 7.4.
I Measured by acridine orange titration (see reference 13).
§ The modes of the size distributions of these fractions were essen-
tially indistinguishable even though some enrichment of the HA
fraction in larger chains and of the VLA fraction in smaller chains
was evident.
matography was a gift from Dr. Michael Blackburn. Human
HC II was isolated by a modification of the procedure of
Tollefson (1) using heparin-agarose affinity chromatography
and DEAE-cellulose anion-exchange chromatography. He-
paran sulfate, isolated from beef-lung byproducts, was ob-
tained from Dr. J. A. Cifonelli. Dermatan sulfate was ob-
tained from Miles Laboratories, Inc. (Elkhart, IN) and was
treated with nitrous acid to remove trace heparin contam-
inants (14).
Heparin activity determination. Thrombin inhibition
was assayed in a two-stage amidolytic assay. AT (75 nM) or
HC 11 (150 nM), thrombin (36 nM), and heparin (total vol-
ume of 0.3 ml in 0.05 M Tris, pH 7.5, 0.15 M NaCl, 1.0 mg/
ml bovine serum albumin) were incubated at 37°C for 60
s in a small polyethylene vial. The thrombin remaining was
determined by transferring 0.2 ml to a disposable cuvette
(Sarstedt, Inc., Princeton, NJ) containing 0.55 ml of 0.05 M
Tris, pH 8.3, 0.15 M NaCl, and 1.65 X 10-4 M of the throm-
bin substrate N-ca-p-tosyl-glycine-proline-arginine-p-ni-
troanilide (Chromozym TH; Boehringer Mannheim Bio-
chemicals, Indianapolis, IN). Substrate hydrolysis at 37°C
was monitored by absorbance at 405 nm. Five concentrations
of each heparin, chosen to produce 10-90% thrombin inhi-
bition, were assayed. With the standard heparin (Diosynth
BV), these ranged from 0.75 nM uronate to 3.0 nM uronate
with AT and 4.0 to 9.0 nM with HC II, heparin concentra-
tion, C, expressed in terms of uronate concentration. For
each heparin concentration the fractional thrombin inhibi-
tion, F, was calculated as (AAo- AAh)/AA01, where AA is
the absorbance change per minute, subscript 0 being without
heparin (but with inhibitor and thrombin), and subscript h
being with heparin. Double-reciprocal plots of 1/F vs. 1/C,
were linear in the range 0.1 < F < 0.9. The concentrations
producing F = 0.5 (C53%) were then interpolated from least-
squares-fitted straight lines. The term CRSO% denotes C30%
(test heparin)/C-0% (standard heparin), both measurements
made under the same conditions of time, temperature, and
protein concentrations. The relative standard deviation of
replicate measurements of CR50% is ±8%. To have larger
numbers associated with more active heparin, we have
elected to equate activity with the reciprocal of CR09'.
RESULTS
The activities of the charge-density fractions and their
AT-affinity subfractions with AT and HC II are shown
in Fig. 1 as a function of Z2. The AT-mediated or HIC
II-mediated activities (1/CR509') of any given charge-
density fractionated heparin before affinity fraction-
ation are essentially indistinguishable and can be de-
scribed by the same linear function of Z2. Note that,
at a given concentration of thrombin and inhibitor,
C50% was higher with the HC II system. However, the
difference in absolute concentrations is equally man-
ifested with both standard and test heparin, thereby
giving identical values of CR50%. As expected, after
fractionation by AT affinity, with AT, the HA fractions
were much more active than were the original frac-
tions while the VLA fractions were virtually inactive.
However the activities of the HA fractions with AT
still depended upon Z2, and the slope of the line is the
same as that observed before fractionation. Moreover,
the slope is independent of the nature of the inhibitor,
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FIGURE 1 Activities (1/CR50°) of heparins in producing
thrombin inhibition with AT and HC II as a function of the
square of charge density (Z2). Activities with AT are shown
using filled symbols and with HC II using open symbols.
O *, heparins before affinity fractionation; O *, HA hepa-
rins; A A, VLA heparins.
with HC II and AT giving the sarne slope. Finally,
fractionation by AT affinity did not affect the activity
of charge-density fractionated heparins in the HC II
system in that HA and VLA heparins, which were
highly active and inactive, respectively, with AT, were
equally active with HC II. Moreover, for each charge
density, the activities with HC II before and after AT-
affinity fractionation are indistinguishable.
The two inhibitors also differed in their patterns of
reactivity with heparan sulfate and derinatan sulfate.
As shown in Table II, heparin-free dermatan sulfate,
which is somewhat active with HC II (-1/200th as
active as the standard heparin), is virtually inactive
with AT. Heparan sulfate showed a very small amount
of activity with AT, but none with HC II. The chon-
droitin sulfate was inactive with either inhibitor.
DISCUSSION
Heparin is not only a complex mixture of different
glycosaminoglycan chains (12), but individual chains
TABLE II
Relative Concentrations of Glycosaminoglycan Required
to Produce 50% Thrombin Inhibition with AT
and HC-II Inhibitors
Inhibitor
Glycosaminoglycan AT HC II
Standard heparin 1 4
Heparan sulfate 2,600 >8,0001
Dermatan sulfate 5,000 800
Chondroitin 4-sulfate >6,0001 >8,0004
° Absolute concentration is 1.4 nM.
I <10% inhibition at stated concentration.
also seem to have multiple functional domains (6, 7),
some of which have been identified with structural
domains for inhibitor and protease binding (2, 6-8).
In this study, systematically fractionated heparins
were used to functionally isolate the effects of the
charge density and AT-affinity domains. The two-
phase partition method is insensitive to molecular
weight for molecular weights >10,000 and separates
heparins according to charge density (9). The fractions
were then each fractionated by AT affinity into HA
and VLA subfractions of the same charge density. In
this manner we produced three series (the HA, low
affinity [LA], and VLA heparins) of much more ho-
mogeneous heparins with properties that were system-
atically related and that could be used to functionally
isolate the AT affinity and charge-density effects.
Except the VLA heparins, which are inactive with
AT, the activities of the heparins with both inhibitors
show the same correlation with charge density. That
such a charge-density effect is seen at all with the HA
heparins is strong, direct evidence that, as predicted
earlier from indirect evidence (10), the correlation
with Z2 arises from a domain that is independent of
the AT-binding domain on the heparin. Moreover, the
slope of the lines, which is a measure of the change
in activity with Z2, is insensitive to the nature of the
inhibitor and is not changed by AT-affinity fraction-
ation. Thus, the charge-density domain apparently
acts similarly with these two different inhibitors, which
suggests that the mechanism of the charge-density ef-
fect may not involve the inhibitor. One explanation
is that charge density manifests its effect through the
protease-binding domain (6-8).
Although Z2 affects activity with the two different
inhibitors in the same way, HC II does not appear to
require the oligosaccharide-binding sequence required
by AT. This is shown clearly by the failure of frac-
tionation by AT affinity to alter in any way the activity
with HC II. In other words, separating heparins into
fractions such that the chains in one fraction all contain
at least one complete AT-binding site (HA heparins),
and the other in which none of the chains contain such
a site (VLA heparin), did not alter the activity with
HC II with respect to the unfractionated heparin of
the same charge density but heterogeneous in AT af-
finity. Thus, we conclude that if a specific oligosac-
charide sequence is required for heparin binding to
HC II inhibitor, as a recent report suggests (15), it
must be different from that required for antithrombin
binding. More detailed structural work will be re-
quired to determine if a specific oligosaccharide se-
quence is required for HC II binding and, if such ex-
ists, whether it overlaps with or is completely inde-
pendent of the AT-binding oligosaccharide sequence.
One of the difficulties in studies involving heparin
fractionation is that many techniques will separate
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heparin by more than one structural variable at a time.
For example, molecular-weight fractionation leads to
concomitant fractionation by AT affinity and vice
versa (5). It is interesting that AT-affinity fractionation
of charge-density fractionated heparins apparently
produces much less concomitant molecular-weight
fractionation than was observed for heparins that were
heterogeneous in charge density (6). Our data suggest
that possibly confounding concomitant fractionation
may occur when charge-density heterogeneous hepa-
rin is fractionated by AT affinity in that the HA frac-
tion will be selectively enriched in more highly
charged heparins (see Table I). Tollefson and co-work-
ers (1) showed that the HC-II activity of an HA frac-
tion of heparin was higher than that of the heparin
prior to AT-affinity fractionation, which led them to
speculate the HC II and AT required the same oli-
gosaccharide-binding sequence. However, the selec-
tive enrichment of the HA heparin with more highly
charged chains, which as we have shown are more
active with HC II, could account for their observation.
It is thus critically important that individual structural
variables, including charge density, molecular weight,
and inhibitor affinity be each controlled.
Under certain circumstances, the contribution of
thrombin inhibition by HC II may be quite important,
even though its concentration in plasma is lower than
that of AT (1) and requires higher concentrations of
heparin to achieve a given level of activity. Heparin
anticoagulant activity in AT-deficient plasma (16), or
the unexpectedly high anticoagulant activities of hep-
arins with low charge densities (11), may well at least
in part, reflect HC II activity of AT-inactive heparins,
while the small, but significant, anticoagulant activity
of heparin-free dermatan sulfate (14) may reflect the
activity dermatan sulfate has with HC II. The results
also suggest that either heparin-free dermatan sulfate
or VLA heparins might be useful for measuring HC
1I activity in plasma.
In summary, we found that heparin contains a
charge-density domain that not only functioned in-
dependently of the AT-binding domain, but appeared
to function identically with two completely different
inhibitors. We also found that the sequence required
for AT binding is not required for HC II activity. The
use of systematically fractionated heparins, such as we
and others (5-7) have used, offers an inviting path to
eventually understanding the complex problem of re-
lating heparin structure and activity.
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